Key result
Polygenic risk score-guided statin therapy achieves long-term cost-effectiveness in intermediate-risk individuals over 40 years.
Answers are grounded in this paper and cite their sources.
Shows that polygenic risk score–guided statin therapy becomes cost-effective over long time horizons, indicating that precision prevention requires evaluating lifetime clinical benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jamal S. Rana (2026) conducted an editorial in Atherosclerotic cardiovascular disease (ASCVD). Polygenic risk score (PRS)-guided statin therapy vs. Standard care (statins for patients with risk-enhancing factors) was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) at 40 years (ICER SGD 23,667/QALY; QALY gain 0.012, 95% CI -0.062 to 0.087). Polygenic risk score-guided statin therapy became cost-effective over 30 to 40 years, achieving an ICER of SGD 23,667 per QALY at 40 years in intermediate-risk 45-year-olds.
Synapse has enriched 10 related papers. Consider them for comparative context: